Compare RDN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDN | BLCO |
|---|---|---|
| Founded | 1977 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | 2008 | 2022 |
| Metric | RDN | BLCO |
|---|---|---|
| Price | $35.94 | $15.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $40.67 | $18.45 |
| AVG Volume (30 Days) | ★ 1.1M | 469.3K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 5.61 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | $1,197,084,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | $2.66 | $5.59 |
| P/E Ratio | $40.88 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $31.50 | $11.22 |
| 52 Week High | $38.84 | $18.92 |
| Indicator | RDN | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 42.13 |
| Support Level | $34.39 | $15.67 |
| Resistance Level | $37.30 | $16.41 |
| Average True Range (ATR) | 1.05 | 0.38 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 27.00 | 18.00 |
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.